GRAIL, Inc. (GRAL) News
Follow GRAIL, Inc. (GRAL) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 37 public stories across 20 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
GRAIL 3Q 2026: Revenue $37.54M, EPS ($2.21) — 10-Q Summary
GRAIL’s revenue rose 4% year over year, while its net loss widened. Screening revenue increased as Galleri sales volume grew 24%, partly offset by a 9% decline in average selling price after promotional pricing began in
EARNINGS | Nov 05, 2026, 09:18 PM UTC
M
GRAIL Reports Q3 Revenue of $37.5M vs. $44.2M FactSet Estimate
EQUITY | Nov 04, 2026, 09:07 PM UTC
M
GRAIL Reports Q3 2026 Results; Galleri Revenue Rises 14%
Galleri test volume increased about 24% year over year to more than 56,000 in the quarter. The FDA advisory committee voted in favor of approval of GRAIL's Galleri multi-cancer early detection test.
EQUITY | Nov 04, 2026, 09:02 PM UTC
L
Grifal H1 EBITDA €2.3 Mln
Grifal SpA MIL:GRAL:Further company coverage
NEWS | Sep 30, 2026, 05:25 AM UTC
L
Canaccord Genuity maintains Buy rating on GRAIL, $150 price target
Canaccord Genuity maintained their Buy rating on GRAIL's stock with a price target of $150.00.The price target implies an upside of 18.2% from the Sep 25 close of $126.89.Key takeaways from the analyst noteStrong Market
EQUITY | Sep 28, 2026, 12:40 PM UTC
L
Weekly Recap: Galleri benefit, low false positives and Q beat, shares up
GRAIL Inc (NASDAQ:GRAL) gained after FDA staff backed its Galleri test for multi-cancer detection with strong performance and low false positives, the company beat Q results (loss $2.56/sh, revenue $44.69M) and saw Mizuh
EARNINGS | Sep 28, 2026, 11:06 AM UTC
L
Grail Is Maintained at Neutral by Mizuho
Ratings actions from Benzinga: GMT) Grail Price Target Raised to $100.00/Share From $65.00 by MizuhoRatings actions from Benzinga
NEWS | Sep 25, 2026, 12:30 PM UTC
L
Biotech Stocks At 52-Week Highs - CDNA +13%, GRAL +15%, TWST +16%, ADPT, RVTY
WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on September 24, 2026, driven by key catalysts such as reaching certain regulatory milestones or results from clinical trials.CareDx Inc. (CDNA)C
NEWS | Sep 25, 2026, 08:54 AM UTC
L
Grail's Multi-Cancer Blood Test Gets FDA Committee Vote for Premarket Approval
By Katherine HamiltonGrail Inc. received a favorable vote from a Food and Drug Administration panel regarding premarket approval for its Galleri multi-cancer early detection test.The cancer-detection company said the FDA
REGULATION | Sep 23, 2026, 10:35 PM UTC
L
GRAIL, Inc. (GRAL) Wins Favorable FDA Panel Vote on Galleri PMA
An FDA advisory committee voted that benefits of GRAIL’s Galleri multi-cancer early detection test outweigh risks and supported its safety and effectiveness. FDA will make the final PMA decision in the coming months.Mate
REGULATION | Sep 23, 2026, 10:18 PM UTC
L
GRAL - FDA Advisory Committee Votes In Favor of Approval of GRAIL's Galleri® Multi- Cancer Early Detection Test
GRAL - FDA Advisory Committee Votes In Favor of Approval of GRAIL's Galleri® Multi- Cancer Early Detection Test
REGULATION | Sep 23, 2026, 10:18 PM UTC
L
FDA Advisory Committee Votes In Favor of Approval of GRAIL's Galleri® Multi-Cancer Early Detection Test
SUNNYVALE, Calif., Sept. 23, 2026 // -- GRAIL, Inc., a healthcare company whose mission is to detect cancer early when it can be cured, today announced a favorable vote from the Molecular and Clinical Genetics Devices Pa
REGULATION | Sep 23, 2026, 10:18 PM UTC
L
FDA advisers back safety of Grail's cancer test, narrowly endorses efficacy
A panel of outside experts advising the US FDA backed the safety of Grail's NASDAQ:GRAL blood-based cancer detection test, Galleri, on Wednesday, though members were divided on the evidence supporting its effectiveness.W
REGULATION | Sep 23, 2026, 09:43 PM UTC
M
GRAIL shares jump after FDA briefing papers support Galleri review
GRAIL (GRAL) surged 34% on Monday to its best day since February 2025 after the FDA posted briefing papers indicating no particular concerns for Wednesday’s review of the Galleri blood test.
EQUITY | Sep 21, 2026, 08:50 PM UTC
M
Grail shares surge after FDA staff see no major test concerns
US FDA staff reviewers said they did not raise major concerns about the accuracy and safety of Grail’s multi-cancer blood test. Grail’s shares surged 35% on Monday.
EQUITY | Sep 21, 2026, 04:41 PM UTC
H
GRAIL Q2 2026 Earnings Call: Complete Transcript
On Wednesday, GRAIL (NASDAQ: GRAL ) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered APIs. For comprehensive financial data and transcrip
LIVE | Sep 18, 2026, 06:55 AM UTC
L
Grail announces inducement grants under Nasdaq Rule 5635(c)(4)
Grail Inc said it will make inducement grants under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 03, 2026, 09:37 PM UTC
L
GRAIL announces inducement grants under NASDAQ Rule 5635(c)(4)
GRAIL said it is announcing inducement grants under NASDAQ listing rule 5635(c)(4).
EQUITY | Sep 03, 2026, 08:02 PM UTC
L
GRAL - GRAIL to Present at Morgan Stanley's 24th Annual Global Healthcare Conference
GRAL - GRAIL to Present at Morgan Stanley's 24th Annual Global Healthcare Conference
EQUITY | Aug 31, 2026, 08:01 PM UTC
L
GRAL - GRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri® Multi- Cancer Early Detectio
GRAL - GRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri® Multi- Cancer Early Detection Test
REGULATION | Aug 07, 2026, 03:05 PM UTC
H
GRAL Reports Q2 Revenue Up 26% YoY
GRAL Q2 revenue rises 26% to $44.7m
EQUITY | Aug 05, 2026, 08:17 PM UTC
L
GRAL GRAL - GRAIL Reports Second Quarter 2026 Financial Results
GRAL GRAL - GRAIL Reports Second Quarter 2026 Financial Results
EARNINGS | Aug 05, 2026, 08:03 PM UTC
L
GRAL - GRAIL, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - GRAL
GRAL - GRAIL, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - GRAL
EQUITY | Jul 31, 2026, 06:47 AM UTC
L
GRAL to Present at Conference
GRAL presents at growth conference
EQUITY | Jul 30, 2026, 08:02 PM UTC
L
Grail: Lead Plaintiff Deadline
Grail lawsuit lead plaintiff deadline
FX | Jul 30, 2026, 02:07 PM UTC
L
GRAL GRAL - GRAIL to Announce Second Quarter 2026 Financial Results
GRAL GRAL - GRAIL to Announce Second Quarter 2026 Financial Results
EARNINGS | Jul 29, 2026, 08:01 PM UTC
L
$GRAL Fraud Notification: GRAIL, Inc. Sued for Securities Fraud After Trial Results Spark a 50% Stock Drop – Investors Notified to Contact B
A securities fraud class action lawsuit has been filed on behalf of GRAIL investors after its stock plummet
REGULATION | Jul 06, 2026, 10:48 AM UTC
L
GRAL Investors Have Opportunity to Lead GRAIL, Inc. Securities Fraud Lawsuit
GRAL Investors Have Opportunity to Lead GRAIL, Inc. Sec
REGULATION | Jul 06, 2026, 10:44 AM UTC
L
GRAL Investor Alert: GRAIL, Inc. Investors Notified of the Important August 4 Deadline in Filed Securities Fraud Class Action Lawsuit
A securities fraud class action lawsuit has been filed on behalf of GRAIL investors after its stock plummeted 50% because GRAIL allegedly misled investors relating to GRAIL's NHS-Galleri cancer
REGULATION | Jul 05, 2026, 11:12 AM UTC
L
Pomerantz LLP Issues Reminder to Investors in GRAIL, Inc. of Class Action Filing – GRAL
NEW YORK CITY, NY / / July 4, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against
EQUITY | Jul 04, 2026, 10:00 PM UTC
L
$GRAL Stock Loss Notice: GRAIL, Inc. Investors That Lost Money When Stock Plummeted 50% May Have Rights in Securities Fraud Class Action
NEW YORK CITY, NY / / July 4, 2026 / Leading securities law firm
EQUITY | Jul 04, 2026, 10:18 AM UTC
L
GRAL Court Reminder: GRAIL, Inc. Investors are Notified to Act before the Upcoming Securities Fraud Class Action Deadline on August 4
A securities fraud class action lawsuit has been filed on behalf of GRAIL investors after its stock plummeted 50% because GRAIL allegedly misled investors relating to GRAIL's NHS-Galleri cancer
REGULATION | Jul 03, 2026, 07:18 PM UTC
L
GRAIL, Inc. (GRAL) Faces Securities Class Action Amid NHS-Galleri Trial Failure, $2.2B Market Cap Wipeout -- HBSS
SAN FRANCISCO, July 03, 2026 (GLOBE NEWSWIRE) -- On February 20, 2026, GRAIL, Inc. (NASDAQ: GRAL<
EQUITY | Jul 03, 2026, 06:18 PM UTC
L
GRAL Investors Have Opportunity to Lead GRAIL, Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES, July 03, 2026 (GLOBE NEWSWIRE) -
REGULATION | Jul 03, 2026, 01:33 PM UTC
L
Pomerantz LLP Issues Reminder to Shareholders in GRAIL, Inc. of Class Action – GRAL
NEW YORK CITY, NY / / July 3, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against
EQUITY | Jul 03, 2026, 11:01 AM UTC
L
GRAL Shareholder News: GRAIL, Inc. Accused of Making Misrepresentations about its Trial Results in Securities Fraud Class Action – Investors
NEW YORK, July 03, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm
EQUITY | Jul 03, 2026, 10:07 AM UTC
M
GRAL Raises $110M
GRAIL completes $110 million equity financing with Samsung entities
EQUITY | Jun 25, 2026, 01:01 PM UTC